Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis
Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), John Mascarenhas(Tisch Hospital), Jean‐Jacques Kiladjian(Délégation Paris 5), Moshe Talpaz(University of Michigan), Gozde Colak(Morpho (United States)), Aaron T. Gerds(Cleveland Clinic), Adam J. Mead(National Institute for Health and Care Research), Yuri Sheikine(Morpho (United States)), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Éric Jourdan(Université de Nîmes), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Andrew Kuykendall(Moffitt Cancer Center), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Haifa Kathrin Al‐Ali(University Hospital in Halle), Sebastian Grosicki(Medical University of Silesia), Marina Kremyanskaya(Tisch Cancer Institute), Vikas Gupta(Indian Institute of Technology Kanpur), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Srđan Verstovšek(Unknown), Timothy Devos(Rega Institute for Medical Research), Mariëlle J. Wondergem(Amsterdam UMC Location Vrije Universiteit Amsterdam), Alberto Álvarez‐Larrán(Hospital Clínic de Barcelona), Sanjay Akhani(MorphoSys (Germany)), Francesca Palandri(Istituto Oncologico Romagnolo)
Cited by 40
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k